Paul Gurbel
Overview
Explore the profile of Paul Gurbel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1203
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dilli Babu A, Singh S, Thota A, Duhan S, Sainatham C, Gill H, et al.
Int J Cardiol Heart Vasc
. 2024 May;
52:101415.
PMID: 38715853
Vascular endothelial growth factor receptor inhibitors (VEGFRi), namely axitinib, are commonly used chemotherapeutic agents in patients with cancer; however, this medication has a significant cardiovascular side effect profile, such as...
2.
Tantry U, Duhan S, Navarese E, Ramotowski B, Kundan P, Bliden K, et al.
Expert Rev Hematol
. 2023 Jun;
16(8):593-605.
PMID: 37335893
Introduction: Antithrombotic therapy field is undergoing rapid and significant changes during the past decade. In addition to new therapeutic strategies with existing targets, investigators are exploring the potential use of...
3.
Gurbel P, Tantry U, Guimaraes P, Lemos P
EuroIntervention
. 2023 Apr;
18(16):e1304-e1306.
PMID: 37025087
No abstract available.
4.
Kunadian V, Baber U, Pivato C, Cao D, Dangas G, Sartori S, et al.
JACC Cardiovasc Interv
. 2022 Oct;
15(19):1948-1960.
PMID: 36202563
Background: There is a paucity of data regarding the safety and efficacy of different antiplatelet regimens according to standardized body mass index (BMI) categories. Objectives: The aim of this study...
5.
Baber U, Dangas G, Angiolillo D, Cohen D, Sharma S, Nicolas J, et al.
Eur Heart J
. 2020 Oct;
41(37):3533-3545.
PMID: 33085967
Aims: The aim of this study was to determine the effect of ticagrelor monotherapy on clinically relevant bleeding and major ischaemic events in relation to clinical presentation with and without...
6.
Garg A, Rout A, Sharma A, Sargsyan D, Beavers T, Tantry U, et al.
Prog Cardiovasc Dis
. 2020 Apr;
63(3):243-248.
PMID: 32247786
Aims: We aimed to determine the efficacy and safety of different anti-platelet regimens after percutaneous coronary intervention (PCI) with drug eluting stent (DES) implantation using a network meta-analysis of randomized...
7.
Tantry U, Cummings C, Mackrell P, Gonze M, Ulloa K, Bafford R, et al.
Future Cardiol
. 2020 Mar;
16(2):69-75.
PMID: 32129681
COMPASS study demonstrated efficacy of dual pathway inhibition with 2.5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the...
8.
Baber U, Urooj Zafar M, Dangas G, Escolar G, Angiolillo D, Sharma S, et al.
J Am Coll Cardiol
. 2020 Feb;
75(6):578-586.
PMID: 32057371
Background: An evolving strategy in the setting of percutaneous coronary intervention (PCI) involves withdrawal of acetylsalicylic acid (ASA), or aspirin, while maintaining P2Y inhibition. However, the pharmacodynamic effects of this...
9.
Dias J, Lopez-Espina C, Bliden K, Gurbel P, Hartmann J, Achneck H
Platelets
. 2019 Dec;
31(7):932-938.
PMID: 31878831
Knowledge of platelet count and function is key to ensuring appropriate hemostatic management. We hypothesized that the novel, portable TEG®6s coagulation assessment system could evaluate the contribution of both platelet...
10.
Wernly B, Rezar R, Gurbel P, Jung C
J Thromb Thrombolysis
. 2019 Nov;
49(1):173-176.
PMID: 31686298
The optimal duration dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is subject to debate. A short-duration DAPT (one month to three months) followed by P2Y monotherapy instead of...